Drug intelligence / Profile preview

nab-paclitaxel + S-1

Development stage: Unknown
Modality: Small Molecules
Administration: Intravenous, Oral

Overview

Nab-paclitaxel + S-1 (AS) is a chemotherapy combination regimen used primarily for treating various types of cancer, including pancreatic cancer and gastric cancer. Nab-paclitaxel is a solvent-free paclitaxel formulation that eliminates the risk of hypersensitivity reactions and was developed as an albumin-bound form of paclitaxel. S-1 is an oral fluoropyrimidine that combines tegafur (a prodrug of 5-fluorouracil) with two modulators. The combination has shown synergistic effects with good tolerability in preclinical models of pancreatic cancer.

Brand names: Abraxane + S-1ABRAXANE + TS-1
Other names: AS regimen

Targets

ERBB2 (Erb-b2 receptor tyrosine kinase 2)TS (Thymidylate synthase)TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on nab-paclitaxel + S-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on nab-paclitaxel + S-1.

Explore the full profile